Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H3MG
|
|||
| Former ID |
DAP000217
|
|||
| Drug Name |
Felypressin
|
|||
| Synonyms |
Felipresina; Felipressina; Felypressine; Felypressinum; Octapressin; Octopressin; Phelypressin; Felipressina [DCIT]; Phenylalanine Lysine Vasopressin; Felipresina [INN-Spanish]; Felypressine [INN-French]; Felypressinum [INN-Latin]; Octapressin (TN); PLV-2; Felypressin [USAN:INN:BAN]; Vasopressin, Phenylalanyl-Lysyl; L-Cysteinyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-lysylglycinamide cyclic (1-6)disulfide; L-Cysteinyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-lysylglycinamide cyclic (1->6)disulfide; 1-{[19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}prolyllysylglycinamide; 2-(L-Phenylalanine)-8-L-lysinevasopressin; N-[6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Localisation [ICD-11: N.A.] | Approved | [1] | |
| Therapeutic Class |
Vasoconstrictor Agents
|
|||
| Company |
AstraZeneca
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C46H65N13O11S2
|
|||
| Canonical SMILES |
C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=CC=C4)N)C(=O)NC(CCCCN)C(=O)NCC(=O)N
|
|||
| InChI |
1S/C46H65N13O11S2/c47-18-8-7-14-29(40(64)52-23-38(51)62)54-45(69)35-15-9-19-59(35)46(70)34-25-72-71-24-28(48)39(63)55-31(20-26-10-3-1-4-11-26)43(67)56-32(21-27-12-5-2-6-13-27)42(66)53-30(16-17-36(49)60)41(65)57-33(22-37(50)61)44(68)58-34/h1-6,10-13,28-35H,7-9,14-25,47-48H2,(H2,49,60)(H2,50,61)(H2,51,62)(H,52,64)(H,53,66)(H,54,69)(H,55,63)(H,56,67)(H,57,65)(H,58,68)/t28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
|
|||
| InChIKey |
SFKQVVDKFKYTNA-DZCXQCEKSA-N
|
|||
| CAS Number |
CAS 56-59-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:60564
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vasopressin V1a receptor (V1AR) | Target Info | Agonist | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Vascular smooth muscle contraction | ||||
| Reactome | Vasopressin-like receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drug Therapy in Nursing. 2008. By Diane S. Aschenbrenner, Samantha J. Venable. | |||
| REF 2 | Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.